Compare BOW & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BOW | COLL |
|---|---|---|
| Founded | 2020 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 913.3M | 1.5B |
| IPO Year | 2024 | 2015 |
| Metric | BOW | COLL |
|---|---|---|
| Price | $28.66 | $48.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $36.17 | ★ $47.50 |
| AVG Volume (30 Days) | 199.9K | ★ 571.6K |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.10 | N/A |
| EPS | 1.53 | ★ 1.63 |
| Revenue | $519,241,000.00 | ★ $757,067,000.00 |
| Revenue This Year | $16.05 | $26.35 |
| Revenue Next Year | $21.18 | $3.67 |
| P/E Ratio | ★ $18.26 | $30.07 |
| Revenue Growth | ★ 33.44 | 26.34 |
| 52 Week Low | $23.50 | $23.23 |
| 52 Week High | $42.29 | $49.92 |
| Indicator | BOW | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 59.90 | 65.70 |
| Support Level | $27.01 | $47.83 |
| Resistance Level | $29.24 | $49.92 |
| Average True Range (ATR) | 0.90 | 1.31 |
| MACD | 0.17 | -0.27 |
| Stochastic Oscillator | 85.63 | 67.64 |
Bowhead Specialty Holdings Inc offers commercial specialty property and casualty insurance products. The company offers underwriting solutions to various businesses across four underwriting divisions, which include Casualty, Professional Liability, Healthcare Liability, and Baleen Specialty. A majority of its revenue is generated from the Casualty division which specializes in general liability coverage, which protects a company against liability arising from bodily injury, personal injury or property damage, for risks in the construction, distribution, heavy manufacturing, real estate, public entity and hospitality segments and also considers underwriting risks in a broader range of industries. Geographically, the company operates in the United States.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.